Head-to-head analysis: Gritstone bio (NASDAQ:GRTS) & CytRx (NASDAQ:CYTR)


Gritstone bio (NASDAQ:GRTS – Get Rating) and CytRx (NASDAQ:CYTR – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, earnings, dividends and profitability.

Institutional and insider ownership

69.9% of Gritstone bio shares are held by institutional investors. Comparatively, 0.1% of CytRx shares are held by institutional investors. 38.0% of the shares of Gritstone bio are held by insiders of the company. By comparison, 12.8% of CytRx shares are held by company insiders. Strong institutional ownership indicates that endowments, hedge funds, and large fund managers believe a company will outperform the market over the long term.

Volatility and risk

Gritstone bio has a beta of 0.36, indicating its stock price is 64% less volatile than the S&P 500. Comparatively, CytRx has a beta of 1.89, indicating its stock price is 89% more volatile than the S&P 500.

Analyst Notes

This is a summary of the current ratings and recommendations for Gritstone bio and CytRx, as reported by MarketBeat.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
Organic wheel 0 0 1 0 3.00
CytRx 0 0 0 0 N / A

Gritstone bio currently has a consensus price target of $15.00, indicating upside potential of 390.20%. Given the higher possible upside of Gritstone bio, equity research analysts clearly believe that Gritstone bio is more favorable than CytRx.


This table compares the net margins, return on equity and return on assets of Gritstone bio and CytRx.

Net margins Return on equity return on assets
Organic wheel -155.73% -37.44% -29.43%
CytRx N / A -212.62% -115.37%

Valuation and benefits

This table compares the revenue, earnings per share (EPS), and valuation of Gritstone bio and CytRx.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
Organic wheel $48.21 million 4.62 -$75.08 million ($0.95) -3.22
CytRx N / A N / A -$13.18 million ($0.15) -1.00

CytRx has lower earnings, but higher earnings than Gritstone bio. Gritstone bio trades at a lower price-to-earnings ratio than CytRx, indicating that it is currently the more affordable of the two stocks.


Gritstone bio beats CytRx on 7 out of 11 factors compared between the two stocks.

Gritstone Bio Company Profile (Get an evaluation)

Gritstone bio, Inc., a clinical-stage biotechnology company, is engaged in the development of immunotherapies against several types of cancer and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder, and stable microsatellite and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer and shared neoantigen positive tumors. Additionally, it is developing CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional T-cell epitopes of SARS-CoV-2 for broader protection and immunity against SARS variants. -CoV-2; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

CytRx Company Profile (Get an evaluation)

CytRx Corporation, a biopharmaceutical research and development company, focuses on oncology and rare diseases. It engages in the discovery, research and clinical development of novel anti-cancer drug candidates that utilize novel binding technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor level. The Company’s lead candidates include linker-activated drug delivery (LADR)-7, LADR-8, LADR-9 and LADR-10; and aldoxorubicin, a conjugate of the prescribed cytotoxic agent doxorubicin, which binds to circulating albumin in the blood and concentrates the drug at the tumor site. It also provides ACDx, an albumin companion diagnostic product to identify cancer patients who are most likely to benefit from treatment with these drug candidates. CytRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.

Get news and reviews for Gritstone bio Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Gritstone bio and related companies with MarketBeat.com’s free daily email newsletter.

Source link

Comments are closed.